Drugs / EPI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05171166 Background | Dec 2021 → Oct 2025 | hepatocellular carcinoma | Peking University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPI | “lipiodol or microspheres that mixed with EPI” NCT05171166 ↗ |